ArticleBMC pharmacology & toxicology2026
The inhibition of tricin on human liver cytochrome P450 enzymes.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTricin has attracted increasing attention due to its diverse pharmacological properties, highlighting its considerable potential for clinical application. However, its potential for drug-drug interactions (DDIs) and its inhibitory effects on human cytochrome P450 (CYP450) enzymes remain unclear. This study aimed to explore the effect of tricin on CYP450s.
methodsThe inhibitory effect of tricin on CYP450s was evaluated by an in vitro study using human pooled live microsomes (HLMs). Tricin, CYP450 enzymes, and the corresponding substrates were co-incubated with HLMs using a NADPH-generating system, and the HLMs incubated without tricin or positive inhibitors served as the negative control. Corresponding inhibitory parameters were obtained by incubating tricin (0-100 µM) with the specific substrates at different concentrations.
resultsTricin showed a selective inhibitory effect on the activities of CYP1A2, 2D6, and 3A4, with the IC
conclusionsIn vitro HLM study indicated the competitive inhibition of tricin on CYP1A2 and 2D6, while non-competitive inhibition and TDI on CYP3A4, thereby informing its potential for clinical drug interactions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.